Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by PharmaEssentia USA Corporation
CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
April 24, 2024
From
PharmaEssentia USA Corporation
Via
Business Wire
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
November 02, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
PharmaEssentia and MPN Advocacy & Education International Launch New Educational Initiative to Empower People Living With Polycythemia Vera (PV)
September 14, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera
August 04, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera
May 23, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)
May 03, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America
February 23, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
February 02, 2023
From
PharmaEssentia USA Corporation
Via
Business Wire
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey
December 12, 2022
From
PharmaEssentia USA Corporation
Via
Business Wire
Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera
November 03, 2022
From
PharmaEssentia USA Corporation
Via
Business Wire
PharmaEssentia Announces Appointment of Meredith Manning to President of the Americas
May 16, 2022
From
PharmaEssentia USA Corporation
Via
Business Wire
PharmaEssentia Expands U.S. Leadership with Anjana Pursnani, Head of People and Jason Mitch, Head of Market Access
February 16, 2022
From
PharmaEssentia USA Corporation
Via
Business Wire
PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States
December 06, 2021
From
PharmaEssentia USA Corporation
Via
Business Wire
U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)
June 03, 2021
From
PharmaEssentia USA Corporation
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.